Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31402424 | 0.78 | AR (0.41) | SMN1; SMN2KDM4ERAB9APOLBMAPT | |
| SCHEMBL9570634 | 0.76 | PLA2G2A (0.46) | SMN1; SMN2RAB9AMAPT | |
| SCHEMBL11534430 | 0.74 | DAO (0.33) | RAB9APOLB | |
| SCHEMBL5727055 | 0.73 | MAPT (0.40) | SMN1; SMN2RAB9AMAPT | |
| SCHEMBL24169276 | 0.73 | MAPT (0.57) | SMN1; SMN2KDM4ERAB9AMAPT | |
| SCHEMBL837414 | 0.73 | ALPL (0.39) | PKMMAPT | |
| SCHEMBL8534048 | 0.73 | GRIN1 (0.52) | — | |
| SCHEMBL1234559 | 0.73 | SLC22A12 (0.65) | MAOBSLC22A12CYSLTR2CYSLTR1 | |
| SCHEMBL10543991 | 0.73 | CYSLTR1 (0.65) | CYSLTR2CYSLTR1 | |
| SCHEMBL6150323 | 0.72 | LTA4H (0.47) | SMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102014898-B | Tetrazole compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORP | 2013-01-23 | — | — | CN | claimed |
| US-20110206653-A1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-08-25 | — | — | US | claimed |
| JP-4711621-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| CN-102014898-A | Tetrazole compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORP | 2011-04-13 | — | — | CN | claimed |
| EP-2282736-A2 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-02-16 | — | — | EP | claimed |
| US-7851494-B2 | Method for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-12-14 | — | — | US | claimed |
| WO-2009134995-A2 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-11-05 | — | — | WO | claimed |
| US-20070265322-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-11-15 | — | — | US | claimed |
| US-7041659-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2006-05-09 | — | — | US | claimed |
| EP-1461323-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2004-09-29 | — | — | EP | claimed |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | claimed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | claimed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | claimed |
| EP-2282736-B1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2015-11-11 | — | — | EP | disclosed |
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2004-05-13 | — | — | US | disclosed |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | disclosed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092516-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885SMN1; SMN2 1792/4885KDM4E 3793/4885 |
| US-20040092518-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885SMN1; SMN2 1792/4885KDM4E 3793/4885 |
| US-20110206653-A1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | FPR1, CASP1, PON1 | MAOB 4656/4885SMN1; SMN2 3994/4885KDM4E 1444/4885 |
| US-20040077896-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885SMN1; SMN2 1792/4885KDM4E 3793/4885 |
| US-20070265322-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | MAOB 589/4885SMN1; SMN2 1792/4885KDM4E 3793/4885 |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | MAOB 589/4885SMN1; SMN2 1792/4885KDM4E 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.